RetinAI Discovery® UNITY is designed to improve the healthcare decision process in Ophthalmology. It is one platform for unification and structuring of data in a single ecosystem.
By unlocking the power of data, Discovery UNITY helps pharmaceutical and life sciences build unparalleled disease understanding to help guide and accelerate research and development for better patient care.

Single data platform to manage data from different sources and devices, at scale. Access data anytime from anywhere.
Integrated AI technology to extract insights across datasets for a better understanding of diseases and patient groups.


A data insurance policy. Secured storage and archival only accessible to authorized personnel to provide peace-of-mind to an organization’s precious resource, its data.
RetinAI Discovery® platform, RetinAI OCT Atlas® and Macula Biomarkers, as well as LuxIA® (Diabetic Retinopathy Screening model) are CE-marked medical devices in accordance with the Medical Devices Regulation (EU) 2017/745 (CE2797). RetinAI Discovery® platform is also a medical device cleared for clinical use by the FDA. The AI modules for biomarkers, fluid, and layer segmentation and quantification in retinal pathologies are designated as Research Use Only (RUO) in the USA. Please be advised that these tools are not intended to replace professional medical advice, diagnosis, or treatment. We do not warrant or guarantee the clinical accuracy, completeness, or usefulness of any content provided by RUO products. For more information, please read our Privacy Notice (https://www.retinai.com/privacy-policy) and Data Processing Agreement (https://www.retinai.com/data-processing-agreement).
RetinAI Discovery® and RetinAI® are trademarks of Ikerian AG.